Intuitive Surgical, Inc. (NASDAQ: ISRG) is a pioneer in robotic-assisted surgical know-how, growing superior techniques that allow healthcare professionals to carry out minimally invasive procedures with better precision and effectivity. Having efficiently commercialized and scaled its robotic platform, the corporate has greater than 10,000 da Vinci techniques—its flagship product—put in worldwide. Constructing on this established footprint, Intuitive Surgical plans to transition to direct gross sales in components of the European market within the first half of 2026, a transfer geared toward strengthening market presence and enhancing margins.
Estimates
The Sunnyvale, California-based medical machine maker will publish its This fall numbers on Thursday, January 22, at 4:05 pm ET. On common, Wall Avenue analysts count on adjusted earnings of $2.26 per share for the quarter, vs. $2.21 per share in This fall 2024. The optimistic forecast displays an estimated 13.8% development in December-quarter revenues to $2.75 billion. Intuitive Surgical has a robust observe document of outperforming estimates – quarterly revenues and income have constantly crushed estimates for almost three years.
In a preliminary report printed this week, the corporate projected an 18% annual development in worldwide procedures and a 17% rise in Da Vinci procedures through the fourth quarter. Preliminary fourth-quarter income is round $2.87 billion, up 19% from the year-ago quarter.
Intuitive Surgical’s shares began 2026 on a excessive be aware, although momentum light later, with the pullback extending into this week. Even so, the inventory’s most up-to-date shut was above the 52-week common value of $522.66. At one level, the inventory traded near the all-time excessive reached a couple of yr in the past, and ISRG has gained almost 6% over the previous six months.
Double-Digit Acquire
Within the September quarter, adjusted earnings rose to $2.40 per share from $1.84 per share in Q3 2024, exceeding expectations. On a reported foundation, internet revenue was $704 million or $1.95 per share within the third quarter, in comparison with $565 million or $1.56 per share within the prior yr. The underside line benefited from a 23% leap in third-quarter revenues to $2.51 billion, which exceeded analysts’ consensus estimates. Worldwide da Vinci procedures grew roughly 19% year-over-year.
“Demand for da Vinci V upgrades drove robust home placements. We imagine upgrades are an efficient method for purchasers to broaden throughput and capabilities. These capabilities embody power sensing, surgeon autonomy, telepresence, and varied different digital instruments that will result in enhanced understanding of what nice surgical procedure seems to be like and additional adoption of robotic-assisted surgical procedure over time. Moreover, it’s our intent to supply refurbished Xi techniques as a part of our broader portfolio, which is able to assist broaden entry in sure geographies and websites of care,” stated the corporate’s president, David Rosa, within the Q3 FY25 earnings name.
The Market
For a very long time, Intuitive Surgical has benefited from a first-mover benefit, as its da Vinci system was the primary robotic-assisted surgical platform to obtain FDA clearance for common laparoscopic surgical procedure. Through the years, the corporate has maintained its market share by way of a differentiated enterprise mannequin and continued product innovation. Nevertheless, the medical machine market is witnessing elevated competitors — not too long ago, Medtronic launched its Hugo robotic-assisted surgical procedure system within the US after receiving FDA clearance for urologic procedures.
The inventory skilled volatility in early buying and selling on Thursday, after a modest opening. In the meantime, analysts’ optimistic outlook signifies the inventory may regain momentum forward of the upcoming earnings.
